Richard is an internationally respected leader in healthcare and life sciences. He is Founding Director of the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), a major UK initiative aimed at transforming the R&D and regulatory processes in life sciences to bring advances more rapidly and affordably to patients. He is the founder of New Medicine Partners, working with governments and health systems around the world on the transformational power of precision medicine. He chairs the South London Health Innovation Network, accelerating innovation in this region of the National Health System (NHS), and of the corresponding Genomic Medicine Centre. He also chairs Image Analysis, a UK company using MRI to quantify the impact of therapy on disease. He is a board member of Celgene, a major US-based bio-therapeutics company.
His 25-year business career in healthcare has spanned biopharmaceuticals, diagnostics and medical informatics – both in the USA and Europe. As Director General of the Association of the British Pharmaceutical Industry, Richard was a board member of both EFPIA and IFPMA, co-founded Life Sciences UK, was a member of the NHS Stakeholder Forum and vice-chair of the UK Clinical Trials Collaboration. In these and many other roles he has advised successive UK governments on healthcare issues, especially those relating to developing, valuing and using new healthcare technologies.
His past leadership roles include head of McKinsey’s European healthcare practice, General Manager of Healthcare Solutions for IBM and Chief Executive of Chiron Diagnostics. He was also Chairman and Chief Executive of Molecular Staging, a US bioscience company, now part of Qiagen.
His book on the future of healthcare 2030 – The Future of Medicine: Avoiding a Medical Meltdown and his second book Bioscience – lost in translation? are published by Oxford University Press. He speaks frequently on the future of life sciences and the restructuring of healthcare systems that new technology can enable.